{"id":743050,"date":"2023-03-28T08:06:14","date_gmt":"2023-03-28T12:06:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"},"modified":"2023-03-28T08:06:14","modified_gmt":"2023-03-28T12:06:14","slug":"soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","title":{"rendered":"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">REDWOOD CITY, Calif., March  28, 2023  (GLOBE NEWSWIRE) &#8212; Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time.<\/p>\n<p>A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=41d_fosPP6NU2Tkft8Nt_Knn-Vw3edH4A2tNPH1nvwvVO0L7yx0z8sYQasFmhIEe5LWpHsy0Y4yVJ158mhBbaA==\" rel=\"nofollow noopener\" target=\"_blank\">www.soleno.life<\/a>.<\/p>\n<p>\n        <strong>About\u00a0Soleno Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company\u2019s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=41d_fosPP6NU2Tkft8Nt_A-HgDgYo3BeG1UpCE9CF6rE6D5hmmG7ackVmei3MmRA1RKFtay0VpCQ84EpTtFMQg==\" rel=\"nofollow noopener\" target=\"_blank\">www.soleno.life<\/a>.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>Brian Ritchie<br \/>LifeSci Advisors, LLC<br \/>212-915-2578<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODU2OGYyNmEtMWJkMC00YzU4LTk1OTItYjM3ZjAxZGEyOTRhLTUwMDA3Mjk5OQ==\/tiny\/Soleno-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company\u2019s website at www.soleno.life. About\u00a0Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company\u2019s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-743050","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company\u2019s website at www.soleno.life. About\u00a0Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company\u2019s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the &hellip; Continue reading &quot;Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T12:06:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days\",\"datePublished\":\"2023-03-28T12:06:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\"},\"wordCount\":167,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\",\"name\":\"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==\",\"datePublished\":\"2023-03-28T12:06:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","og_locale":"en_US","og_type":"article","og_title":"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days - Market Newsdesk","og_description":"REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company\u2019s website at www.soleno.life. About\u00a0Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company\u2019s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the &hellip; Continue reading \"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-28T12:06:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days","datePublished":"2023-03-28T12:06:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"},"wordCount":167,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","name":"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==","datePublished":"2023-03-28T12:06:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NCM1NDk0NjEzIzUwMDA3Mjk5OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/743050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=743050"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/743050\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=743050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=743050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=743050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}